Efficacy of Anti-CTLA-4 Antibody Combined With Sintilimab and Chemotherapy as Neoadjuvant Therapy for Resectable Stage II-III Non-Small Cell Lung Cancer

This study aims to evaluate the major pathologic response (MPR) rate of neoadjuvant therapy with sintilimab (PD-1 inhibitor) + IBI310 (anti-CTLA-4 antibody) + chemotherapy, and to assess the efficacy of this treatment strategy in patients with PD-L1-negative stage II - IIIB (excluding N3) NSCLC (according to AJCC 9th) scheduled for surgery.

NCT Number	NCT07410975
Lead Sponsor	Shanghai Pulmonary Hospital, Shanghai, China
Conditions	NSCLC Stage II, NSCLC Stage III
Enrollment	54 participants
Start Date	2026-01-10
Primary Completion	2028-06-10 (estimated)
Study Completion	2030-01-10 (estimated)
Updated on ClinicalTrials.gov	2026-02-13